Bizily Scott sold $92K of FDMT
Bizily Scott (Chief Legal Officer) sold 6,566 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $14.00 on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific insider sale size, price, and post-transaction holdings, with a stated 10b5-1 pre-arranged plan.
Market read
Traders may monitor FDMT insider activity, but this particular disclosure is unlikely to drive a fundamental repricing given the 10b5-1 context.
What to watch
The filing does not state any change in business outlook, and the share price reaction, if any, would be driven by trader interpretation rather than new fundamentals.
Background
The article is a SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
FDMT disclosed a Form 4 showing CFO Bizily Scott sold 6,566 shares at $14.00 on June 30 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven rather than news-driven.
The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not include new operating, clinical, or financial guidance.
Market effects
No clear sector read-through; this is company-specific insider trading disclosure.
None.
None.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity needs rather than bearish expectations.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Company that filed the Form 4 insider transaction disclosure.
- insiderBizily Scott
Chief Legal Officer who sold shares under a 10b5-1 plan.
